Bill > SB696

This bill establishes the Pharmaceutical Transparency Review Board, an independent board tasked with reviewing high-cost prescription drug products and developing recommendations to address affordability issues for residents, government agencies, health plans, providers, employers, and pharmacies in Pennsylvania. The bill requires manufacturers to report detailed information about the costs and pricing of certain high-cost drugs, which the Board will use to analyze and publish reports on prescription drug affordability. The Board is funded through assessments on manufacturers and can impose penalties on non-compliant manufacturers. The bill also requires the Board to submit annual reports on pricing trends and recommendations for making prescription drugs more affordable in the state.